Föreläsningar och seminarier PCM föreläsning: Rethinking Precision Cancer Medicine: Innovations in Clinical Trial Designs and Beyond

2024-02-22 14:00 Add to iCal
Campus Solna Eva and Georg Klein lecture hall, Biomedicum, KI Solna campus, Solnavägen 9

Talare: Lillian L. Siu
Director, Phase I Program, Chair in Precision Genomics, Princess Margaret Cancer Centre, University of Toronto, Canada

Lillian L. Siu, MD, FASCO

BMO Chair in Precision Genomics, Director of Phase I Program, Professor of Medicine, Princess Margaret Cancer Centre, Toronto, Canada

Dr. Siu is a senior medical oncologist at Princess Margaret Cancer Centre since 1998, and has been a Professor of Medicine at the University of Toronto since 2009. She is the Director of the Phase I Program and Co-Director of the Bras and Family Drug Development Program at Princess Margaret Cancer Centre, and holds the BMO Chair in Precision Genomics (2016-2026).  She is also the Clinical Lead for the Tumor Immunotherapy Program at Princess Margaret Cancer Centre. Dr. Siu served on the Board of Directors for the American Society of Clinical Oncology (ASCO) for a four-year term (2012-2016) and was Chair of the ASCO Conquer Cancer Foundation Grants Selection Committee in 2019; she served on the American Association for Cancer Research (AACR) Board of Directors for a three-year term (2017-2020). Dr. Siu is a fellow of ASCO and newly elected into the AACR fellowship academic (class of 2024).

Dr. Siu’s major research focus is in the area of new anticancer drug development, particularly with respect to phase I trials and head and neck malignancies.  She is the co-Contact PI of a phase I UM1 grant sponsored by the United States National Cancer Institute. In addition to her active research in early phase clinical trials, she has been leading genomics initiatives and immuno-oncology trials at the Princess Margaret Cancer Centre. Together, the three programs of drug development, cancer genomics and tumor immunotherapy form a triad of synergy that supports the institution’s core vision to deliver precision cancer medicine. Internationally, Dr. Siu was the recipient of the US NCI Michaele C. Christian Award in Oncology Drug Development in 2010.  She was awarded the TAT 2020 Honorary Award for contributions in the development of anticancer drugs.  In 2023, Dr. Siu was recognized for her educational efforts by the ASCO International Women Who Conquer Cancer Mentorship Award. Dr. Siu has published 400 peer-reviewed manuscripts, and she is currently the co-Editor-in-Chief for AACR’s newest journal Cancer Research Communications, and is on the editorial board for Cell and Cancer Cell


Host: Ingemar Ernberg